(Circulation. 1995;91:691-697.)
© 1995 American Heart Association, Inc.
Articles |
Losartan in Heart Failure
Hemodynamic Effects and Tolerability
From the Christchurch Hospital (I.C., H.I.), Christchurch, New Zealand; Minerva Consertal (N.A.), Sacramento, Calif; Hammersmith Hospital (J.C., N.S.), London, UK; Central Hospital in Rogaland (K.D.), Stavanger, Norway; Sarasota Heart Institute (M.F.), Sarasota, Fla; Baylor College of Medicine (J.Y.), Houston, Tex; and Merck Research Laboratories (G.K., L.M., E.R.), West Point, Pa.
Correspondence to Dr Ian Crozier, Department of Cardiology, Christchurch Hospital, Riccarton Ave, Private Bag, Christchurch, New Zealand.
Background The aim of the present study was to assess the short- and long-term effects of multiple doses of the angiotensin II receptor antagonist losartan in heart failure.
Methods and Results A multicenter, placebo-controlled,
oral, multidose (2.5, 10, 25, and 50 mg losartan once daily)
double-blind comparison in patients with symptomatic heart failure and
impaired left ventricular function (ejection fraction <40%). Invasive
24-hour hemodynamic assessment was performed after the first dose and
after 12 weeks of treatment. Clinical status and tolerability of
treatment with losartan over the 12-week period were also evaluated.
One hundred fifty-four patients were enrolled, of which 134 met the
protocol criterion of baseline pulmonary capillary wedge pressure 
13
mm Hg. During short-term administration, systemic vascular resistance
(SVR) (largest reduction against placebo of 197
dyne · s-1 · cm-5 at 4 hours)
and
blood pressure fell significantly with 50 mg, lesser decreases were
seen with 25 mg, and no discernible effects were seen with 2.5 and 10
mg. After 12 weeks of treatment, similar effects were seen on SVR and
blood pressure (maximal fall in SVR against placebo, 318
dyne · s-1 · cm-5 at 5 hours
with 50
mg). In addition, pulmonary capillary wedge pressure fell with 2.5, 25,
and 50 mg (largest reduction against placebo of 6.3 mm Hg at 6 hours
with 50 mg), cardiac index rose with 25 and 50 mg, and heart rate was
lower with all active treatment groups. Active treatment was well
tolerated, and excess cough was not reported.
Conclusions This study showed that oral losartan administered to patients with symptomatic heart failure resulted in beneficial hemodynamic effects with short-term administration, with additional beneficial hemodynamic effects seen after 12 weeks of therapy. Clear effects were seen with both 25 and 50 mg, with the greatest effect seen with 50 mg.
Key Words: losartan • heart failure • angiotensin
This article has been cited by other articles:
 |
|
 |
|
  S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]
|
|
|
|
|
|
M. Jessup, W. T. Abraham, D. E. Casey, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. A. Konstam, D. M. Mancini, P. S. Rahko, M. A. Silver, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1343 - 1382. [Full Text] [PDF]
|
|
|
|
 |
|
 2009 WRITING GROUP TO REVIEW NEW EVIDENCE AND UPDA, M. Jessup, W. T. Abraham, D. E. Casey, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. A. Konstam, D. M. Mancini, P. S. Rahko, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): 1977 - 2016. [Full Text] [PDF]
|
|
|
|
|
|
2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]
|
|
|
|
 |
|
 M.A.C. Onuigbo Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ontarget--a call for more circumspection QJM, March 1, 2009; 102(3): 155 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. Kemi, M. A. Hoydal, P. M. Haram, A. Garnier, D. Fortin, R. Ventura-Clapier, and O. Ellingsen Exercise training restores aerobic capacity and energy transfer systems in heart failure treated with losartan Cardiovasc Res, October 1, 2007; 76(1): 91 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Akbulut, H. Akgoz, S. U. Dayi, S. E. Celik, U. Gurkan, and G. Tayyareci Evaluation of Enalapril+Losartan Treatment with Cardiopulmonary Exercise Test in Patients with Left Ventricular Dysfunction Angiology, March 1, 2006; 57(2): 181 - 186. [Abstract] [PDF]
|
|
|
|
|
|
Developed in Collaboration With the American Colle, Endorsed by the Heart Rhythm Society, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1116 - 1143. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society Circulation, September 20, 2005; 112(12): 1825 - 1852. [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Lee, D. C. Rhew, M. Dylan, E. Badamgarav, G. D. Braunstein, and S. R. Weingarten Meta-Analysis: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction Ann Intern Med, November 2, 2004; 141(9): 693 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nap, C. N. Belterman, M.-J. Mathy, J. C Balt, M. Pfaffendorf, and P. A van Zwieten Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model Journal of Renin-Angiotensin-Aldosterone System, December 1, 2003; 4(4): 220 - 227. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi Addition of Valsartan to an Angiotensin-Converting Enzyme Inhibitor Improves Cardiac Sympathetic Nerve Activity and Left Ventricular Function in Patients with Congestive Heart Failure J. Nucl. Med., June 1, 2003; 44(6): 884 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. McClean, H. Ikram, S. Mehta, J. T. Heywood, M. F. Rousseau, A. L. Niederman, R. F. Sequeira, E. Fleck, S. N. Singh, B. Coutu, et al. Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects J. Am. Coll. Cardiol., June 19, 2002; 39(12): 2034 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jong, C. Demers, R. S. McKelvie, and P. P. Liu Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials J. Am. Coll. Cardiol., February 6, 2002; 39(3): 463 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Khaper and P. K. Singal Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1461 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Jamali, W. H. W. Tang, U. N. Khot, and M. B. Fowler The Role of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure Arch Intern Med, March 12, 2001; 161(5): 667 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Burnier Angiotensin II Type 1 Receptor Blockers Circulation, February 13, 2001; 103(6): 904 - 912. [Full Text] [PDF]
|
|
|
|
|
|
Q.-G. Xia, O. Chung, H. Spitznagel, S. Illner, G. Janichen, B. Rossius, P. Gohlke, and T. Unger Significance of timing of angiotensin AT1 receptor blockade in rats with myocardial infarction-induced heart failure Cardiovasc Res, January 1, 2001; 49(1): 110 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Grossman, F. H. Messerli, and J. M. Neutel Angiotensin II Receptor Blockers: Equal or Preferred Substitutes for ACE Inhibitors? Arch Intern Med, July 10, 2000; 160(13): 1905 - 1911. [Full Text] [PDF]
|
|
|
|
|
|
J. McMurray and C. Berry Ongoing clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 131 - 136. [PDF]
|
|
|
|
 |
|
 S. Kumar, D. R. Maurya, M. Chandra, S. Kumar, D. R. Maurya, and M. Chandra ACE Inhibition Versus Angiotensin-II Antagonism in Heart Failure Asian Cardiovasc Thorac Ann, June 1, 2000; 8(2): 195 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure J. Am. Coll. Cardiol., March 1, 2000; 35(3): 714 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Witte, S. Thackray, T. Banerjee, A. L. Clark, and J. G.F. Cleland Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure Eur J Heart Fail, March 1, 2000; 2(1): 107 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Girgrah, P Liu, J Collier, L Blendis, and F Wong Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis Gut, January 1, 2000; 46(1): 114 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Houghton, M. Harrison, and A. J. Cowley Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy Eur J Heart Fail, December 17, 1999; 1(4): 385 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. McKelvie, S. Yusuf, D. Pericak, A. Avezum, R. J. Burns, J. Probstfield, R. T. Tsuyuki, M. White, J. Rouleau, R. Latini, et al. Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure : Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study: The RESOLVD Pilot Study Investigators Circulation, September 7, 1999; 100(10): 1056 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Di Pasquale, V Bucca, S Scalzo, S Cannizzaro, A Giubilato, and S Paterna Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study Heart, June 1, 1999; 81(6): 606 - 611. [Abstract] [Full Text]
|
|
|
|
|
|
L. Baruch, I. Anand, I. S. Cohen, S. Ziesche, D. Judd, and J. N. Cohn Augmented Short- and Long-Term Hemodynamic and Hormonal Effects of an Angiotensin Receptor Blocker Added to Angiotensin Converting Enzyme Inhibitor Therapy in Patients With Heart Failure Circulation, May 25, 1999; 99(20): 2658 - 2664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhang, B. S. Huang, and F. H. H. Leenen Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction Am J Physiol Heart Circ Physiol, May 1, 1999; 276(5): H1608 - H1615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Havranek, I. Thomas, W. B. Smith, G. A. Ponce, M. Bilsker, M. A. Munger, R. A. Wolf, and for the Irbesartan Heart Failure Group Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1174 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tanimura, V. G. Sharov, H. Shimoyama, T. Mishima, T. B. Levine, S. Goldstein, and H. N. Sabbah Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure Am J Physiol Heart Circ Physiol, April 1, 1999; 276(4): H1385 - H1392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hamroff, S. D. Katz, D. Mancini, I. Blaufarb, R. Bijou, R. Patel, G. Jondeau, M.-T. Olivari, S. Thomas, and T. H. Le Jemtel Addition of Angiotensin II Receptor Blockade to Maximal Angiotensin-Converting Enzyme Inhibition Improves Exercise Capacity in Patients With Severe Congestive Heart Failure Circulation, March 2, 1999; 99(8): 990 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Brodsky, K. Gurbanov, Z. Abassi, A. Hoffman, R. R. Ruffolo Jr, G. Z. Feuerstein, and J. Winaver Effects of Eprosartan on Renal Function and Cardiac Hypertrophy in Rats With Experimental Heart Failure Hypertension, October 1, 1998; 32(4): 746 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. Abraham Pharmacologic Management of Chronic Heart Failure: A Review Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 168 - 190. [Abstract] [PDF]
|
|
|
|
|
|
D E Newby, N E R Goodfield, A D Flapan, N A Boon, K A A Fox, and D J Webb Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II Heart, August 1, 1998; 80(2): 134 - 140. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Gambaryan, C. Wagner, A. Smolenski, U. Walter, W. Poller, W. Haase, A. Kurtz, and S. M. Lohmann Endogenous or overexpressed cGMP-dependent protein kinases inhibit cAMP-dependent renin release from rat isolated perfused kidney, microdissected glomeruli, and isolated juxtaglomerular cells PNAS, July 21, 1998; 95(15): 9003 - 9008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A D STRUTHERS Angiotensin II receptor antagonists for heart failure Heart, July 1, 1998; 80(1): 5 - 6. [Full Text]
|
|
|
|
|
|
R.S. Krombach, M. J Clair, J. W Hendrick, W. V Houck, J. L Zellner, S. B Kribbs, S. Whitebread, R. Mukherjee, M. de Gasparo, and F. G Spinale Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns Cardiovasc Res, June 1, 1998; 38(3): 631 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Bosch Henoch-Schonlein Purpura Induced by Losartan Therapy Arch Intern Med, January 26, 1998; 158(2): 191 - 192. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Bosch Losartan-Induced Hepatotoxicity JAMA, November 19, 1997; 278(19): 1572 - 1572. [Abstract] [PDF]
|
|
|
|
|
|
D. E Newby, S. Masumori, N. R Johnston, N. A Boon, and D. J Webb Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man Cardiovasc Res, November 1, 1997; 36(2): 268 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Spinale, M. de Gasparo, S. Whitebread, L. Hebbar, M. J. Clair, D. M. Melton, R. S. Krombach, R. Mukherjee, J. P. Iannini, and S.-J. O Modulation of the Renin-Angiotensin Pathway Through Enzyme Inhibition and Specific Receptor Blockade in Pacing-Induced Heart Failure : I. Effects on Left Ventricular Performance and Neurohormonal Systems Circulation, October 7, 1997; 96(7): 2385 - 2396. [Abstract] [Full Text]
|
|
|
|
|
|
F. G. Spinale, R. Mukherjee, J. P. Iannini, S. Whitebread, L. Hebbar, M. J. Clair, D. M. Melton, M. H. Cox, P. B. Thomas, and P. B. Marc de Gasparo Modulation of the Renin-Angiotensin Pathway Through Enzyme Inhibition and Specific Receptor Blockade in Pacing-Induced Heart Failure : II. Effects on Myocyte Contractile Processes Circulation, October 7, 1997; 96(7): 2397 - 2406. [Abstract] [Full Text]
|
|
|
|
|
|
F. H. Messerli, M. A. Weber, and H. R. Brunner Angiotensin II Receptor Inhibition: A New Therapeutic Principle Arch Intern Med, September 23, 1996; 156(17): 1957 - 1965. [Abstract] [PDF]
|
|
|
|
 |
|
 T. L. Goodfriend, M. E. Elliott, and K. J. Catt Angiotensin Receptors and Their Antagonists N. Engl. J. Med., June 20, 1996; 334(25): 1649 - 1655. [Full Text] [PDF]
|
|
|
|
|
|
F. Pieruzzi, Z. A. Abassi, and H. R. Keiser Expression of Renin-Angiotensin System Components in the Heart, Kidneys, and Lungs of Rats With Experimental Heart Failure Circulation, November 15, 1995; 92(10): 3105 - 3112. [Abstract] [Full Text]
|
|